TY - JOUR
T1 - Benzopyrimido-pyrrolo-oxazine-dione CFTR inhibitor (R)-BPO-27 for antisecretory therapy of diarrheas caused by bacterial enterotoxins
AU - Cil, Onur
AU - Phuan, Puay Wah
AU - Gillespie, Anne Marie
AU - Lee, Sujin
AU - Tradtrantip, Lukmanee
AU - Yin, Jianyi
AU - Tse, Ming
AU - Zachos, Nicholas C.
AU - Lin, Ruxian
AU - Donowitz, Mark
AU - Verkman, Alan S.
N1 - Publisher Copyright:
© FASEB.
PY - 2017/2
Y1 - 2017/2
N2 - Secretory diarrheas caused by bacterial enterotoxins, including cholera and traveler's diarrhea, remain a major global health problem. Inappropriate activation of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel occurs in these diarrheas. We previously reported that the benzopyrimido-pyrrolooxazinedione (R)-BPO-27 inhibits CFTR chloride conductancewith low-nanomolar potency.Here, we demonstrate using experimentalmouse models andhumanenterocyte cultures the potentialutility of (R)-BPO-27 for treatment of secretory diarrheas caused by cholera and Escherichia coli enterotoxins. (R)-BPO-27 fully blocked CFTR chloride conductance in epithelial cell cultures and intestine after cAMP agonists, cholera toxin, or heat-stable enterotoxin of E. coli (STa toxin), with IC50 down to ∼5 nM. (R)-BPO-27 prevented cholera toxin and STa toxin-induced fluid accumulation in small intestinal loops, with IC50 down to 0.1 mg/kg. (R)-BPO-27 did not impair intestinal fluid absorption or inhibit other major intestinal transporters. Pharmacokinetics in mice showed >90% oral bioavailability with sustained therapeutic serum levels for >4 h without the significant toxicity seen with 7-d administration at 5 mg/kg/d. As evidence to support efficacy in human diarrheas, (R)-BPO-27 blocked fluid secretion in primary cultures of enteroids fromhuman small intestine and anion current in enteroidmonolayers. These studies support thepotentialutility of (R)-BPO-27 for therapy ofCFTR-mediated secretorydiarrheas.-Cil, O., Phuan, P.-W., Gillespie, A. M., Lee, S., Tradtrantip, L., Yin, J., Tse, M., Zachos, N. C., Lin, R., Donowitz, M., Verkman, A. S. Benzopyrimido-pyrrolo-oxazine-dioneCFTR inhibitor (R)-BPO-27 for antisecretory therapy of diarrheas caused by bacterial enterotoxins.
AB - Secretory diarrheas caused by bacterial enterotoxins, including cholera and traveler's diarrhea, remain a major global health problem. Inappropriate activation of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel occurs in these diarrheas. We previously reported that the benzopyrimido-pyrrolooxazinedione (R)-BPO-27 inhibits CFTR chloride conductancewith low-nanomolar potency.Here, we demonstrate using experimentalmouse models andhumanenterocyte cultures the potentialutility of (R)-BPO-27 for treatment of secretory diarrheas caused by cholera and Escherichia coli enterotoxins. (R)-BPO-27 fully blocked CFTR chloride conductance in epithelial cell cultures and intestine after cAMP agonists, cholera toxin, or heat-stable enterotoxin of E. coli (STa toxin), with IC50 down to ∼5 nM. (R)-BPO-27 prevented cholera toxin and STa toxin-induced fluid accumulation in small intestinal loops, with IC50 down to 0.1 mg/kg. (R)-BPO-27 did not impair intestinal fluid absorption or inhibit other major intestinal transporters. Pharmacokinetics in mice showed >90% oral bioavailability with sustained therapeutic serum levels for >4 h without the significant toxicity seen with 7-d administration at 5 mg/kg/d. As evidence to support efficacy in human diarrheas, (R)-BPO-27 blocked fluid secretion in primary cultures of enteroids fromhuman small intestine and anion current in enteroidmonolayers. These studies support thepotentialutility of (R)-BPO-27 for therapy ofCFTR-mediated secretorydiarrheas.-Cil, O., Phuan, P.-W., Gillespie, A. M., Lee, S., Tradtrantip, L., Yin, J., Tse, M., Zachos, N. C., Lin, R., Donowitz, M., Verkman, A. S. Benzopyrimido-pyrrolo-oxazine-dioneCFTR inhibitor (R)-BPO-27 for antisecretory therapy of diarrheas caused by bacterial enterotoxins.
KW - Cholera
KW - Intestinal secretion
KW - Secretory diarrhea
KW - Traveler's diarrhea
UR - http://www.scopus.com/inward/record.url?scp=85011290518&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85011290518&partnerID=8YFLogxK
U2 - 10.1096/fj.201600891R
DO - 10.1096/fj.201600891R
M3 - Article
C2 - 27871064
AN - SCOPUS:85011290518
SN - 0892-6638
VL - 31
SP - 751
EP - 760
JO - FASEB Journal
JF - FASEB Journal
IS - 2
ER -